Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 15NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Radiotherapy 213Cisplatin 180Cyclophosphamide 168Doxorubicin 135Paclitaxel 125Vincristine 124Filgrastim 121Etoposide 103Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NETWORK × brivanib × Clear all
NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Canadian Cancer Trials Group

Phase 3 Completed
750 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01267253 2019-03-20

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
31 enrolled 9 charts
Gynecologic

Uterine Cervical Neoplasms

NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡